- Germany’s leading medical cannabis company, Sanity Group has entered strategic agreement with longtime investor and partner, Organigram Global Inc.
- Transaction valuation: Sanity Group has been valued at a total of up to EUR 250 million, consisting of an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for twelve months ending March 31, 2027
- This catalyzes Sanity Group’s long term international growth and international expansion across the European cannabis market
As one of Germany’s leading companies in the medical cannabis sector, Sanity Group has entered into an agreement on a strategic transaction with its long-standing investor and production partner, Organigram Global Inc. (“Organigram”). Based on two highly complementary business models, the two companies are pursuing an integrated approach that prioritizes global growth, diversification of the product portfolio, and, in turn, a sustainable improvement in the supply of cannabis patients. The publicly listed Toronto-headquartered company Organigram [1] contributes extensive expertise in quality-assured cultivation, processing and innovative cannabis product development to the partnership—complementing Sanity Group’s capabilities and experience to create a strong foundation for long-term growth and international expansion across the European cannabis market. Sanity Group will continue to focus on the pharmaceutical segment, confirms founder and CEO Finn Hänsel: “Building on our complementary strengths and synergies, we and Organigram plan not only to sustainably secure the supply of cannabis for patients in Europe, but to strengthen it over the long term. Our focus on distributing medical cannabis to pharmacies, as well as on scientific research and innovation, therefore remains unchanged.”
